Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age

Lars Henning Pedersen, Tine Brink Henriksen and Jørn Olsen
Pediatrics March 2010, 125 (3) e600-e608; DOI: https://doi.org/10.1542/peds.2008-3655
Lars Henning Pedersen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tine Brink Henriksen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jørn Olsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

OBJECTIVE: The goal was to investigate a possible association between exposure to antidepressants in utero and developmental milestones in early childhood.

METHODS: Information on pregnancy exposures and developmental milestones at 6 and 19 months was obtained from the Danish National Birth Cohort. Of the eligible pregnant women, 415 used antidepressant medication, 489 reported depression with no medical treatment, and 81 042 reported no depression and no use of psychotropic medication.

RESULTS: Children with second- or third-trimester exposure to antidepressants were able to sit 15.9 days (95% confidence interval [CI]: 6.8–25.0) and to walk 28.9 days (95% CI: 15.0–42.7) later than children of women not exposed to antidepressants but still were within the normal range of development. Fewer children with second- or third-trimester exposure to antidepressants were able to sit without support at 6 months of age (odds ratio: 2.1 [95% CI: 1.23–3.60]), and fewer were able to occupy themselves at 19 months of age (odds ratio: 2.1 [95% CI: 1.09–4.02]). None of the other milestones measured showed statistically significant associations with antidepressant exposure.

CONCLUSION: The results of this study suggest a permanent or reversible effect of antidepressant exposure on fetal brain development, which may depend on the timing of exposure during pregnancy.

  • neurobehavioral behavior
  • selective serotonin reuptake inhibitor
  • prenatal exposure
  • serotonin
  • Accepted October 7, 2009.
  • Copyright © 2010 by the American Academy of Pediatrics

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 125, Issue 3
1 Mar 2010
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age
Lars Henning Pedersen, Tine Brink Henriksen, Jørn Olsen
Pediatrics Mar 2010, 125 (3) e600-e608; DOI: 10.1542/peds.2008-3655

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age
Lars Henning Pedersen, Tine Brink Henriksen, Jørn Olsen
Pediatrics Mar 2010, 125 (3) e600-e608; DOI: 10.1542/peds.2008-3655
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSIONS
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Mediation analysis in sibling designs: an application to the effect of prenatal antidepressant exposure on toddler depression mediated by gestational age at birth
  • Protocol for a feasibility randomised trial of low-intensity interventions for antenatal depression: ADAGIO trial comparing interpersonal counselling with cognitive behavioural therapy
  • Prenatal Antidepressant Exposure and Child Motor Development: A Meta-analysis
  • Pharmacology Review: Maternal Selective Serotonin Reuptake Inhibitor Use and Neurologic Effects on the Neonate
  • Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children
  • Beyond Classical Inheritance: The Influence of Maternal Genotype upon Child's Brain Morphology and Behavior
  • Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay
  • Paroxetine is associated with malformation during pregnancy
  • Google Scholar

More in this TOC Section

  • Neonatal SARS-CoV-2 Infections in Breastfeeding Mothers
  • Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act
  • Clinical Impact of a Diagnostic Gastrointestinal Panel in Children
Show more 25

Similar Articles

Subjects

  • Fetus/Newborn Infant
    • Fetus/Newborn Infant
  • Developmental/Behavioral Pediatrics
    • Developmental/Behavioral Pediatrics
    • Growth/Development Milestones
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics